Regeneron Pharmaceuticals PT Raised to $348.00 at RBC Capital (REGN)
RBC Capital upped their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $344.00 to $348.00 in a research note issued on Thursday, Stock Ratings Network.com reports. RBC Capital’s price target indicates a potential upside of 8.72% from the stock’s previous close.
In other Regeneron Pharmaceuticals news, Director Alfred G. Gilman sold 5,000 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $320.00, for a total transaction of $1,600,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 320.38 on Thursday. Regeneron Pharmaceuticals has a 52 week low of $154.16 and a 52 week high of $331.64. The stock’s 50-day moving average is $285. and its 200-day moving average is $280.. The company has a market cap of $31.469 billion and a price-to-earnings ratio of 46.49.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, February 11th. The company reported $2.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the prior year, the company posted $1.47 earnings per share. The company’s quarterly revenue was up 47.0% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $6.21 EPS for the current fiscal year.
A number of other firms have also recently commented on REGN. Analysts at Goldman Sachs raised their price target on shares of Regeneron Pharmaceuticals from $353.00 to $383.00 in a research note on Thursday. Separately, analysts at Bank of America initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Wednesday. They set a “buy” rating and a $387.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals to $410.00 in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Buy” and an average target price of $314.97.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.